More than 46 million Germans have now received a third corona vaccination as a booster. But the next dose is already up for debate. Health Minister Karl Lauterbach apparently doubts whether this actually makes sense for everyone.
–
Loud current figures from the Robert Koch Institute (RKI), almost 56 percent of Germans have received a third corona vaccination. However, it remains to be seen whether that will do the trick. At the beginning of the month, the Standing Committee on Vaccination (Stiko) recommended a fourth dose for people who are particularly at risk (the stern reported).
Experts disagree on how useful double boosters actually are. Federal Health Minister Karl Lauterbach (SPD) is also apparently skeptical about the fourth vaccination. On Wednesday, Lauterbach shared a tweet from the scientific director of the Leipniz Institute at the TU Dortmund, Carsten Watzl. The head of the immunology department had shared data from an Israeli study, according to which a fourth dose of vaccine had “little benefit at the current time with the current vaccine”. “These data from Israel tend to speak against a 4th vaccination for everyone,” Lauterbach tweeted.
–
” vendor-id=”5e71760b69966540e4554f01″ vendor-name=”Twitter”/>
According to preliminary study results: Fourth vaccination is only marginally effective
According to the preprint of the study, the researchers examined the effects of a fourth dose in terms of the omicron variant. The scientists primarily looked at safety and immunogenicity (ability of an antigen to trigger an immune response). But the effectiveness of the fourth vaccination was also part of the study. These factors were tested on 55- to 60-year-old healthcare workers.
Protestkonvoi in Paris
Action “of phenomenal proportions”: The Canadian trucker protests have become a role model for the French
14 images
The result: The fourth vaccination just produces the antibody level that is reached shortly after the third dose is administered. The protection against symptomatic infections is only 30 to 40 percent. “The low efficacy in preventing mild or asymptomatic omicron infections and the infectious potential of breakthrough cases make the development of a next-generation vaccine urgently needed,” the study authors continue.
Those: Preprint of the study on medrxiv.org
one
–
Related